Drug Type CAR-T |
Synonyms- |
Target |
Mechanism GD2 inhibitors(Disialoganglioside GD2 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroblastoma | Phase 1 | CN | 01 Jan 2016 |
Phase 1 | 10 | 4SCAR-GD2 T-cell | bnwxdjqyzg(djbmxremeq) = Grade 3 or 4 hematological toxicities were the common adverse events frequently occurred after fludarabine and cyclophosphamide (Flu/cy) chemotherapy. Grade 1-2 toxicities such as cytokine release syndrome (CRS) and neuropathic pain were common, but were transient and mild. cjqmdpfihc (mqottxgdnz ) | Positive | 01 Nov 2021 |